Urgent.News

What's breaking now, across thousands of outlets.

Business

Wagniskapital: Citi Ventures beteiligt sich an Berliner Karten-Fintech Pliant

Der Spezialist für Firmenkreditkarten sammelt 80 Millionen Dollar bei Investoren ein, unter anderem bei Citi. Welches strategische Interesse verfolgt die Großbank mit der Beteiligung?

Original German Read in English

Wagniskapital: Citi Ventures beteiligt sich an Berliner Karten-Fintech Pliant

Citi Ventures has invested $80 million (approximately €71 million) in Berlin-based fintech company Pliant, as part of a funding round led by Seaya Nova and Speedinvest. The round of investment doubles the amount Pliant raised in the previous year, which was $40 million. Other investors in the round include Illuminate Financial, Motive Partners, and Molten Ventures.

Citigroup, through its in-house venture capital arm, is also participating in the funding round. Citi is a major player in the travel industry, with high trade volumes handled through credit cards and a platform in partnership with Booking.com. Pliant offers a digital credit card solution to companies, travel agencies, and tourism providers.

The fintech collaborates with Visa on this solution. Pliant's CEO, Malte Rau, expressed hope for a mutually beneficial partnership with Citi. The fintech industry valuation in Germany is currently at two to six times annual recurring revenue, with Pliant being valued at an upper-end valuation. After the latest funding round, Pliant shifted its profitability goal to 2028, with the company currently operating at a loss of around €11.5 million annually.

Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at handelsblatt.com →

More in Business

Lonza Acquires Merck U.S. CDMO Facilities, Competing with Samsung Biologics

Swiss Lonza, a global contract development and manufacturing organization (CDMO) company, will acquire the United States CDMO business of German Merck.With Samsung Biologics in the process of…

  • Lonza acquires Merck's U.S. CDMO facilities for $126.3M-$769.2M
  • Expansion to nine U.S. locations and 6,000 employees
  • Wisconsin facility specializes in anticancer drug ingredients

More from Wednesday 4 November →